ClinGen髓系恶性肿瘤变异解读专家小组对胚系RUNX1变异的推荐
ClinGen髓系恶性肿瘤变异解读专家小组(MM-VCEP)针对遗传性髓系恶性肿瘤,对2015年ACMG/AMP指南的28条规则进行RUNX1基因特异性优化,包括计算最小等位基因频率阈值、半定量计数独立变异事件、识别功能域和突变热点、建立功能实验阈值及表型特异性指南。在52个变异试点中应用RUNX1特异性标准后,意义不明变异(VUS)和冲突解读(CONF)减少了33%。
要点
- MM-VCEP对RUNX1胚系变异制定基因特异性ACMG/AMP解读标准。
- 优化包括最小等位基因频率阈值、功能域与突变热点等关键规格。
- 试点52个变异中,应用新标准使VUS和CONF减少33%。
核心结论
- RUNX1特异性ACMG/AMP标准可减少意义不明变异和冲突解读,支持基因特异性解读和实验室内部数据共享。
研究设计与样本
- MM-VCEP由美国血液学会与ClinGen合作创建,针对遗传性髓系恶性肿瘤优化RUNX1变异解读规则。
- 使用52个变异组成的试点集测试初步规则,其中50个在ClinVar中已有既往分类。
主要发现
- 应用RUNX1特异性标准后,冲突解读和意义不明变异减少了33%。
关键数值与推荐
- 对28条ACMG/AMP规则进行RUNX1特异性调整,包括计算最小等位基因频率阈值、半定量计数多个独立变异事件、识别功能域和突变热点、建立功能实验阈值及表型特异性指南。
临床怎么用
- 临床可应用RUNX1特异性标准对胚系RUNX1变异进行标准化解读,减少解读差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Standardized variant curation is essential for clinical care recommendations for patients with inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are developing disease-associated gene specifications using the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to reduce curation discrepancies. The ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) was created collaboratively between the American Society of Hematology and ClinGen to perform gene- and disease-specific modifications for inherited myeloid malignancies. The MM-VCEP began optimizing ACMG/AMP rules for RUNX1 because many germline variants have been described in patients with familial platelet disorder with a predisposition to acute myeloid leukemia, characterized by thrombocytopenia, platelet functional/ultrastructural defects, and a predisposition to hematologic malignancies. The 28 ACMG/AMP codes were tailored for RUNX1 variants by modifying gene/disease specifications, incorporating strength adjustments of existing rules, or both. Key specifications included calculation of minor allele frequency thresholds, formulating a semi-quantitative approach to counting multiple independent variant occurrences, identifying functional domains and mutational hotspots, establishing functional assay thresholds, and characterizing phenotype-specific guidelines. Preliminary rules were tested by using a pilot set of 52 variants; among these, 50 were previously classified as benign/likely benign, pathogenic/likely pathogenic, variant of unknown significance (VUS), or conflicting interpretations (CONF) in ClinVar. The application of RUNX1-specific criteria resulted in a reduction in CONF and VUS variants by 33%, emphasizing the benefit of gene-specific criteria and sharing internal laboratory data.
引用
- Luo X, Feurstein S, Mohan S, et al. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Adv. 2019. PMID: 31648317. doi:10.1182/bloodadvances.2019000644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。